Carboplatin

Results: 150



#Item
1A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

Add to Reading List

Source URL: s3.amazonaws.com

- Date: 2014-09-25 16:14:56
    2Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in patients (pts) with recurrent platinum-sensitive ovarian cancer (OC) Roisin O’Cearbhaill1, Scott McM

    Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in patients (pts) with recurrent platinum-sensitive ovarian cancer (OC) Roisin O’Cearbhaill1, Scott McM

    Add to Reading List

    Source URL: s3.amazonaws.com

    - Date: 2016-06-05 05:57:06
      3A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1McKeage D,

      A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1McKeage D,

      Add to Reading List

      Source URL: s3.amazonaws.com

      Language: English - Date: 2016-06-04 05:54:29
      4CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for

      CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for

      Add to Reading List

      Source URL: www.ctc.usyd.edu.au

      Language: English - Date: 2016-03-21 02:14:55
      5A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Kotasek 3 Markman

      A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Kotasek 3 Markman

      Add to Reading List

      Source URL: posters.omed.s3.amazonaws.com

      Language: English - Date: 2015-06-01 00:20:16
        6A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1McKeage 2 M, Kotasek

        A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1McKeage 2 M, Kotasek

        Add to Reading List

        Source URL: posters.omed.s3.amazonaws.com

        Language: English - Date: 2015-04-15 19:58:21
          7ANEXANumăr de citări în reviste de specialitate cotate ISI 1 Denumire Articol Clinical effects of erdosteine in the treatment

          ANEXANumăr de citări în reviste de specialitate cotate ISI 1 Denumire Articol Clinical effects of erdosteine in the treatment

          Add to Reading List

          Source URL: www.cdt-babes.ro

          Language: English - Date: 2009-08-31 04:44:23
          8Carboplatin/Gemcitabin (lungcancermg/m

          Carboplatin/Gemcitabin (lungcancermg/m

          Add to Reading List

          Source URL: www.cancercentrum.se

          - Date: 2013-05-15 07:28:32
            9Microsoft Word - 2. Carboplatin_5FU pump _H&N_doc

            Microsoft Word - 2. Carboplatin_5FU pump _H&N_doc

            Add to Reading List

            Source URL: www.cancercentrum.se

            - Date: 2012-02-21 11:22:00
              10Carboplatin/Bevacizumab (bröstca) Bevacizumab (Avastin) 5 mg/kg cykelintervall 14 dagar

              Carboplatin/Bevacizumab (bröstca) Bevacizumab (Avastin) 5 mg/kg cykelintervall 14 dagar

              Add to Reading List

              Source URL: www.cancercentrum.se

              - Date: 2012-10-12 04:35:35